Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2010: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Research Abstract |
Enforced expressions of miR-199a and miR-101, of which expressions are inhibited in renal cell cancer (RCC), leads to suppression of GSK3β and EZH2 resulting in reducing cancer cell proliferation. Re-introduction of miR-199a and/or miR-101 might be a beneficial treatment strategy. Reduced expression of ATBF1 is correlated with more malignant character of RCC. hsa-miR-203, hsa-miR-194, hsa-miR-204 are proposed as suppressors of ATBF1 might be novel targets for another new treatment modality.
|